Thalassemia major Thalassemia major HRV parameters Magnetic resonance acquisition N-
Conditions
Interventions
NAC long 600 mg: Active ingredient is Acetylcysteine.
,Placebo Comparator is the tablet of Maize starch.
Active Comparator Drug,Placebo Comparator No treatment
acetylcysteine (NAC),Placebo
Sponsors
The Faculty of Medicine Endowment fund
The Faculty of Medicine Endowment fund
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All diagnosed thalassemia major patients aged 18 years or older currently treated with regular blood transfusion and iron chelation therapy
Exclusion criteria
Exclusion criteria: Patients will be excluded if they have apparent heart diseases, diabetes mellitus, atrial flutter, atrial fibrillation, thyrotoxicosis, pacemaker installation, or had been taking any medications, which affected autonomic function including contraceptive, tricyclic antidepressant, anticholinergic agents, amphotericin B, calcium channel blocker, beta-blocker, antiarrhythmic, and centrally acting antihypertensive agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of HRV after NAC therapy compared to placebo 12 months Holter monitor | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of myocardial iron after NAC therapy compared to placebo 12 months Magnetic resonance acquisition,The change of left ventricular function after NAC therapy compared to placebo 12 months Echocadiogram,The change of oxidative stress and inflammatory markers after NAC therapy compared to placebo 12 months Blood collection for inflammatory markers and oxidative stress test | — |
Countries
Thailand
Contacts
Public ContactArintaya Phrommintikul
Faculty of Medicine, Chiang Mai University
Outcome results
None listed